Table 2.
Estimated means from models at T2 and T3
| Scale range | Duloxetine intervention | Care-as-usual | Adjusted mean difference | P-value | |
|---|---|---|---|---|---|
| T2 (after treatment phase) | |||||
| KOOS/HOOS | |||||
| Pain | 0–100 | 45.3 (41.4, 49.2) | 34.0 (30.1, 37.9) | 11.3 (5.8, 16.8) | < 0.001 |
| Symptoms | 0–100 | 49.1 (44.7, 53.5) | 39.9 (35.5, 44.3) | 9.2 (3.0, 15.4) | 0.004 |
| ADL | 0–100 | 47.8 (43.5, 52.1) | 37.3 (33.0, 41.6) | 10.5 (4.5, 16.6) | 0.001 |
| QOL | 0–100 | 26.8 (22.8, 30.8) | 22.3 (18.3, 26.4) | 4.5 (0.5, 12.3) | 0.124 |
| mPDQ | −1-38 | 11.7 (10.3, 13.2) | 15.4 (13.9, 16.8) | 3.6 (1.6, 5.7) | 0.001 |
| VAS-past week | |||||
| VAS-Rest | 0–100 | 40.8 (34.8, 46.8) | 57.8 (51.8, 63.8) | 17.0 (8.5, 25.5) | < 0.001 |
| VAS-Movement | 0–100 | 53.9 (48.9, 59.1) | 70.6 (65.6, 75.7) | 16.7 (9.5, 23.9) | < 0.001 |
| PGI-Ia | 1–7 | 3.3 ± 1.7 | 5.0 ± 0.9 | 1.77 (1.2, 2.3) | < 0.001 |
| Much or very much better# | 43.8% (21/48) | 0% (0/51) | – | < 0.001 | |
| Much or very much worse# | 12.5% (6/48) | 33.3% (17/51) | – | 0.018 | |
| T3 (after tapering phase) | |||||
| KOOS/HOOS | |||||
| Pain | 0–100 | 43.1 (39.2, 47.0) | 36.4 (32.6, 40.3) | 6.7 (1.2, 12.1) | 0.017 |
| Symptoms | 0–100 | 44.8 (40.5, 49.2) | 41.7 (37.4, 46.1) | 3.1 (−2.8, 10.5) | 0.325 |
| ADL | 0–100 | 45.5 (41.2, 49.7) | 40.2 (36.0, 44.5) | 5.2 (−0.8, 11.2) | 0.089 |
| QOL | 0–100 | 27.0 (23.0, 31.0) | 22.3 (18.3, 26.4) | 4.7 (−1.0, 10.4) | 0.105 |
| mPDQ | −1-38 | 13.0 (11.6, 14.4) | 15.1 (13.7, 16.6) | 2.1 (0.1, 4.2) | 0.04 |
| VAS-past week | |||||
| VAS-Rest | 0–100 | 42.6 (36.6, 48.6) | 60.3 (54.3, 66.3) | 17.7 (9.3, 26.2) | < 0.001 |
| VAS-Movement | 0–100 | 58.8 (53.8, 63.8) | 69.2 (64.2, 74.3) | 10.4 (3.3, 17.6) | 0.004 |
| PGI-Ia | 1–7 | 4.0 ± 1.6 | 5.2 ± 1.1 | 1.2 (0.7, 1.7) | < 0.001 |
| Much or very much better# | . | 22.5% (11/49) | 0% (0/51) | – | < 0.001 |
| Much or very much worse# | 22.5% (11/49) | 51.0% (26/51) | – | 0.004 | |
aobserved values; # % (n/N)